6Z7G

N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH N-(2-(1H-imidazol-4-yl)ethyl)-4-acetamido-3-(benzyloxy)benzamide

これはPDB形式変換不可エントリーです。

6Z7G の概要

• エントリーDOI: 10.2210/pdb6z7g/pdb
• 分子名称: Bromodomain-containing protein 4, N-(2-(1H-imidazol-4-yl)ethyl)-4-acetamido-3-(benzyloxy)benzamide (3 entities in total)
• 機能のキーワード: inhibitor, histone, epigenetic reader, bromodomain, brd4, bromodomain containing protein 4, antagonist, transcription
• 由来する生物種: Homo sapiens (Human)
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 15477.80

構造登録者

Chung, C. (登録日: 2020-05-30, 公開日: 2020-07-29, 最終更新日: 2024-05-15)

主引用文献

Preston, A.,Atkinson, S.,Bamborough, P.,Chung, C.W.,Craggs, P.D.,Gordon, L.,Grandi, P.,Gray, J.R.J.,Jones, E.J.,Lindon, M.,Michon, A.M.,Mitchell, D.J.,Prinjha, R.K.,Rianjongdee, F.,Rioja, I.,Seal, J.,Taylor, S.,Wall, I.,Watson, R.J.,Woolven, J.,Demont, E.H.
Design and Synthesis of a Highly Selective andIn Vivo-Capable Inhibitor of the Second Bromodomain of the Bromodomain and Extra Terminal Domain Family of Proteins.
J.Med.Chem., 63:9070-9092, 2020

PubMed Abstract: Pan-bromodomain and extra terminal domain (BET) inhibitors interact equipotently with the eight bromodomains of the BET family of proteins and have shown profound efficacy in a number of phenotypic assays and pre-clinical models in inflammation or oncology. A number of these inhibitors have progressed to the clinic where pharmacology-driven adverse events have been reported. To better understand the contribution of each domain to their efficacy and improve their safety profile, selective inhibitors are required. This article discloses the profile of GSK046, also known as iBET-BD2, a highly selective inhibitor of the second bromodomains of the BET proteins that has undergone extensive pre-clinical and characterization.

PubMed: 32691591
DOI: 10.1021/acs.jmedchem.0c00605

実験手法

X-RAY DIFFRACTION (1.59 Å)